Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors. View the full release here: https://www.businesswire.com/news/home/20230322005004/en/In addition to the financing, Dr. Rick Kuntz, MD, MSc, former Senior Vice President, Chief Medical and Scientific Officer of Medtronic and Helen Liang, Founder & Managing Partner at FoundersX, will join Cognitos Board of Directors. There is an urgent need to develop novel therapies that can safely delay the onset and progression of these neurodegenerative conditions, said Brent Vaughan, CEO, Cognito Therapeutics. This funding will accelerate development of Cognitos home-based wearable device which has the potential to be a novel, safe, disease-modifying therapeutic approach to treat neurodegenerative diseases, starting with Alzheimers. Cognito is a pioneer at the unique intersection of biology and technology in using neuromodulation to potentially alter the trajectory of neurodegenerative diseases, and were thrilled to support the advancement of this pivotal study in Alzheimers.Cognitos device is limited by United States law to investigational use only and is not available for sale.